Advantage Investment Management’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Advantage Investment Management’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-300	Closed	-$12K	–	1036
2018 Q4	$12K	Hold	300	–	–	0.01%	628
2018 Q3	$16K	Hold	300	–	–	0.01%	632
2018 Q2	$25K	Hold	300	–	–	0.02%	503
2018 Q1	$20K	Buy	300 +150	+100%	+$8.66K	0.01%	555
2017 Q4	$8K	Hold	150	–	–	﹤0.01%	745
2017 Q3	$13K	Hold	150	–	–	﹤0.01%	646
2017 Q2	$9K	Hold	150	–	–	﹤0.01%	733
2017 Q1	$8K	Hold	150	–	–	﹤0.01%	738
2016 Q4	$7K	Hold	150	–	–	﹤0.01%	706
2016 Q3	$9K	Hold	150	–	–	﹤0.01%	643
2016 Q2	$8K	Hold	150	–	–	﹤0.01%	643
2016 Q1	$4K	Hold	150	–	–	﹤0.01%	724
2015 Q4	$7K	Hold	150	–	–	﹤0.01%	644
2015 Q3	$6K	Hold	150	–	–	﹤0.01%	640
2015 Q2	$9K	Buy	+150	New	+$9.92K	﹤0.01%	621

Other funds holding ONCE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Advantage Investment Management's ONCE Position: Q1 2019 in Review

Advantage Investment Management sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q1 2019, closing a stake of 300 shares — an estimated $12K sold.

Advantage Investment Management first reported a position in ONCE in Q2 2015 and held it in 15 quarters. The position peaked at $25K in Q2 2018. 199 funds tracked by Wall St. Rank hold ONCE as of Q1 2019.

Advantage Investment Management reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Advantage Investment Management sold 300 Spark Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $12K.
Advantage Investment Management first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 15 quarters.
Advantage Investment Management's Spark Therapeutics, Inc. Common Stock position peaked at $25K in Q2 2018.
199 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Advantage Investment Management's 13F filing for Q1 2019, filed 15 May 2019.